NCT06160128 Clinical Outcomes and Pharmacotherapy Effectiveness in the VA Health Care System (COPE-VA)
| NCT ID | NCT06160128 |
| Status | Recruiting |
| Phase | — |
| Sponsor | VA Office of Research and Development |
| Condition | COVID-19, SARS-CoV-2 Infection |
| Study Type | OBSERVATIONAL |
| Enrollment | 400,000 participants |
| Start Date | 2022-09-26 |
| Primary Completion | 2026-09-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 400,000 participants in total. It began in 2022-09-26 with a primary completion date of 2026-09-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The purpose of this study is to comprehensively describe the temporal and geographic utilization of COVID-19 therapies used for mild to moderate disease during different periods of SARS-CoV-2 variant circulation as well as to compare demographic and clinical characteristics of Veterans who are treated or do not receive these different therapies. The investigators will also perform similar descriptive epidemiology for other respiratory viruses, including RSV and influenza and other infectious diseases. This first phase will critically inform feasibility and direction of the second phase, in which the investigators will use target trial emulation design to study the comparative effectiveness of therapies and vaccines for COVID-19, respiratory viruses, including RSV, and influenza, and other infectious diseases.
Eligibility Criteria
Inclusion Criteria: Phase 1: \- Veterans aged 18 years with a laboratory-confirmed positive test for SARS-CoV-2 or a diagnosis of COVID-19 documented at any time since the beginning of the pandemic in January 2020 to present. Phase 2: * All Veterans aged 18 years alive and in VHA care as of January 2018. * Specific exclusion/inclusion criteria and observation periods will be further defined for each sub-study (See outcomes/publications). Exclusion Criteria: * VA employees who are not enrollees
Contact & Investigator
Kristina L Bajema, MD
STUDY CHAIR
VA Portland Health Care System, Portland, OR
Frequently Asked Questions
Who can join the NCT06160128 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying COVID-19, SARS-CoV-2 Infection. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06160128 currently recruiting?
Yes, NCT06160128 is actively recruiting participants. Contact the research team at Kristina.Bajema@va.gov for enrollment information.
Where is the NCT06160128 trial being conducted?
This trial is being conducted at Portland, United States.
Who is sponsoring the NCT06160128 clinical trial?
NCT06160128 is sponsored by VA Office of Research and Development. The principal investigator is Kristina L Bajema, MD at VA Portland Health Care System, Portland, OR. The trial plans to enroll 400,000 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.